Afficher la notice abrégée

Plasma concentrations of lipoproteins and risk of lower-limb peripheral artery disease in people with type 2 diabetes: the SURDIAGENE study

dc.rights.licenseopenen_US
dc.contributor.authorBERTRAND, Capucine
dc.contributor.authorSAULNIER, Pierre-Jean
dc.contributor.authorPOTIER, Louis
dc.contributor.authorCROYAL, Mikael
dc.contributor.authorBLANCHARD, Valentin
dc.contributor.authorGAND, Elise
dc.contributor.authorRAGOT, Stephanie
dc.contributor.authorSCHNEIDER, Fabrice
dc.contributor.authorBOCOCK, Olivia
dc.contributor.authorBAILLET-BLANCO, Laurence
dc.contributor.authorVELHO, Gilberto
dc.contributor.authorMARRE, Michel
dc.contributor.authorROUSSEL, Ronan
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorRIGALLEAU, Vincent
dc.contributor.authorHADJADJ, Samy
hal.structure.identifierBiologie des maladies cardiovasculaires = Biology of Cardiovascular Diseases
dc.contributor.authorMOHAMMEDI, Kamel
dc.date.accessioned2021-04-19T12:25:12Z
dc.date.available2021-04-19T12:25:12Z
dc.date.issued2021-03
dc.identifier.issn1432-0428 (Electronic) 0012-186X (Linking)en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/26966
dc.description.abstractEnAIMS/HYPOTHESIS: The lipid profile has not been fully investigated in individuals with peripheral artery disease (PAD). We aimed to evaluate the relationship between plasma concentrations of lipoproteins and the prevalence of lower-limb PAD at baseline and its incidence during follow-up in people with type 2 diabetes. METHODS: Plasma concentrations of total cholesterol, HDL-cholesterol, triacylglycerol and apolipoprotein (Apo) A-I, ApoA-II, ApoB-100 and Apo(a) were measured at baseline using colorimetric or MS methods in the SURDIAGENE cohort. Total cholesterol/HDL-cholesterol ratio, non-HDL-cholesterol and LDL-cholesterol were estimated using computation formulas. Logistic and Cox proportional hazard regression models were fitted to estimate OR or HR, with related 95% CI, for baseline prevalence or incidence of major PAD (lower-limb amputation or requirement of revascularisation) during follow-up by increasing lipoprotein tertiles, after adjustment for key confounders. RESULTS: Among 1468 participants (women 42%, mean ± SD age 65 ± 11 years, duration of diabetes 14 ± 10 years at baseline), 129 (8.8%) had a baseline history of major PAD. Major PAD was less prevalent at baseline in the highest (vs lowest) tertile of HDL-cholesterol (OR 0.42 [95% CI 0.26, 0.71], p = 0.001) and ApoA-I (OR 0.39 [95% CI 0.23, 0.67], p = 0.0007), and more frequent in the highest tertile of total cholesterol/HDL-cholesterol ratio (OR 1.95 [95% CI 1.18, 3.24], p = 0.01). Among 1339 participants without a history of PAD at baseline, incident PAD occurred in 97 (7.2%) during a median (25th-75th percentile) duration of follow-up of 7.1 (4.4-10.7) years, corresponding to 9685 person-years and an incidence rate of 9.8 (95% CI 8.0, 12.0) per 1000 person-years. The risk of incident PAD was lower in the top (vs bottom) tertile of HDL-cholesterol (HR 0.54 [95% CI 0.30, 0.95], p = 0.03) or ApoA-I (HR 0.50 [95% CI 0.28, 0.86], p = 0.01) and higher in the top tertile of total cholesterol/HDL-cholesterol ratio (HR 2.81 [95% CI 1.61, 5.04], p = 0.0002) and non-HDL-cholesterol (HR 1.80 [95% CI 1.06, 3.12], p = 0.03). CONCLUSIONS/INTERPRETATION: We reported independent associations between HDL-cholesterol, ApoA-I, total cholesterol/HDL-cholesterol ratio or non-HDL-cholesterol and the prevalence or the incidence of major PAD in people with type 2 diabetes. Our findings provide a picture of lipoprotein profile in people with type 2 diabetes. Graphical abstract.
dc.language.isoENen_US
dc.subject.enApolipoproteins
dc.subject.enLimb loss
dc.subject.enLipids
dc.subject.enLipoproteins
dc.subject.enLower-limb amputation
dc.subject.enPeripheral arterial disease
dc.subject.enRevascularisation
dc.subject.enType 2 diabetes
dc.title.enPlasma concentrations of lipoproteins and risk of lower-limb peripheral artery disease in people with type 2 diabetes: the SURDIAGENE study
dc.title.alternativeDiabetologiaen_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1007/s00125-020-05326-xen_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed33409569en_US
bordeaux.journalDiabetologiaen_US
bordeaux.page668-680en_US
bordeaux.volume64en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - U1219en_US
bordeaux.issue3en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.teamLEHA_BPH
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
bordeaux.identifier.funderIDMinistère des Solidarités et de la Santéen_US
hal.identifierhal-03201993
hal.version1
hal.date.transferred2021-04-19T12:25:18Z
hal.exporttrue
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Diabetologia&rft.date=2021-03&rft.volume=64&rft.issue=3&rft.spage=668-680&rft.epage=668-680&rft.eissn=1432-0428%20(Electronic)%200012-186X%20(Linking)&rft.issn=1432-0428%20(Electronic)%200012-186X%20(Linking)&rft.au=BERTRAND,%20Capucine&SAULNIER,%20Pierre-Jean&POTIER,%20Louis&CROYAL,%20Mikael&BLANCHARD,%20Valentin&rft.genre=article


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée